The PI3Kα/γ/δ inhibitor, taselisib, in combination with fulvestrant, exhibits clinical benefit for metastatic ER+ breast cancers associated with multiple PIK3CA mutations [12]. The gene discussed is PIK3CA; the disease is breast carcinoma.